Brought to you by 
Edison Pharma completes $20.1mm Series F round
03 Dec 2012
Executive Summary
Just over a year after completing a $4mm Series E round, Edison Pharmaceuticals Inc. (redox-directed drug candidates for orphan mitochondrial disorders) has raised $20.1mm in a Series F financing led by Mitsui & Co. Global Investment, which will contribute a new board member. Five other undisclosed backers participated. Edison is putting the money towards Phase IIb trials of EPI743, a small molecule targeting NADPH quinone oxidoreductase for Leigh syndrome--a neurological condition resulting in progressive loss of mental and movement abilities--and Friedreich’s ataxia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Edison Pharma completes $20.1mm Series F round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice